Pharmacological characterization of LY293284: A 5-HT1A receptor agonist with high potency and selectivity.

Autor: Foreman, M M, Fuller, R W, Rasmussen, K, Nelson, D L, Calligaro, D O, Zhang, L, Barrett, J E, Booher, R N, Paget, C J, Flaugh, M E

Publikováno v: The Journal of Pharmacology and Experimental Therapeutics; September 1994, Vol. 270 Issue: 3 p1270-1281, 12p

Characterization of binding, functional activity, and contractile responses of the selective 5-HT1F receptor agonist lasmiditan.

Autor: Rubio‐Beltrán, Eloísa¹ (AUTHOR), Labastida‐Ramírez, Alejandro¹ (AUTHOR), Haanes, Kristian A.¹ (AUTHOR), Bogaerdt, Antoon² (AUTHOR), Bogers, Ad J.J.C.² (AUTHOR), Zanelli, Eric³ (AUTHOR), Meeus, Laurent⁴ (AUTHOR), Danser, A.H. Jan¹ (AUTHOR), Gralinski, Michael R.⁵ (AUTHOR), Senese, Peter B.⁵ (AUTHOR), Johnson, Kirk W.⁶ (AUTHOR), Kovalchin, Joseph⁷ (AUTHOR), Villalón, Carlos M.⁸ (AUTHOR), MaassenVanDenBrink, Antoinette¹ (AUTHOR) a.vanharen‐maassenvandenbrink@erasmusmc.nl, Rubio-Beltrán, Eloísa⁹ (AUTHOR), Labastida-Ramírez, Alejandro⁹ (AUTHOR), van den Bogaerdt, Antoon¹⁰ (AUTHOR)

Publikováno v: British Journal of Pharmacology. Dec2019, Vol. 176 Issue 24, p4681-4695. 15p. 1 Diagram, 2 Charts, 6 Graphs.

Practical Synthesis of 7-Azaserotonin and 7-Azamelatonin.

Autor: Fukuya, Ren, Yamada, Koji, Nishi, Takahide

Publikováno v: Synlett; Dec2022, Vol. 33 Issue 20, p2033-2037, 5p

Azepine-Indole Alkaloids From Psychotria nemorosa Modulate 5-HT2 A Receptors and Prevent in vivo Protein Toxicity in Transgenic Caenorhabditis elegans.

Autor: Kirchweger, Benjamin, Klein-Junior, Luiz C., Pretsch, Dagmar, Chen, Ya, Cretton, Sylvian, Gasper, André L., Heyden, Yvan Vander, Christen, Philippe, Kirchmair, Johannes, Henriques, Amélia T., Rollinger, Judith M.

Publikováno v: Frontiers in Neuroscience; 3/14/2022, Vol. 16, p1-12, 12p

Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments.

Autor: Zobdeh F; Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.; Functional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden., Ben Kraiem A; Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.; Functional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden., Attwood MM; Functional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden., Chubarev VN; Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University, Moscow, Russia., Tarasov VV; Department of Pharmacology, Institute of Pharmacy, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.; Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia., Schiöth HB; Functional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden.; Institute of Translational Medicine and Biotechnology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia., Mwinyi J; Functional Pharmacology, Department of Neuroscience, Uppsala University, Uppsala, Sweden.

Publikováno v: British journal of pharmacology [Br J Pharmacol] 2021 Dec; Vol. 178 (23), pp. 4588-4607. Date of Electronic Publication: 2021 Sep 26.